Show Summary Details
Page of

Malignant hyperthermia 

Malignant hyperthermia
Chapter:
Malignant hyperthermia
Author(s):

PM Hopkins

and A Urwyler

DOI:
10.1093/med/9780199583386.003.0019
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 07 August 2020

Chapter 19 covers malignant hyperthermia, and although much has been learnt about the human condition from work on animals, especially the porcine model of malignant hyperthermia, the chosen papers are restricted to human studies where possible. The one notable exception to this is the paper by Harrison and colleagues, which led to the demonstration of the efficacy of dantrolene in treating malignant hyperthermia. Also excluded is the vast literature that has examined the relationship between malignant hyperthermia and other disorders. These relationships now range from the well-established, such as with central core disease, to the extremely tenuous such as with sudden infant death syndrome. For many other conditions, such as exertional heat stroke, the debate remains more balanced and it would be difficult to do justice to these debates without diluting the impact of research that is focused purely on malignant hyperthermia and hence the decision not to include such work.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.